The European Osteosarcoma Intergroup (E.O.I.) studies 1980–1991
In 1980 there was considerable confusion surrounding the management of osteosarcoma. Those involved in the management of this disease were faced with a series of conflicts. The early promise of chemotherapy as initially reported by Jaffe appeared to have been logically extended by Rosen in a series of studies culminating in the startling results of T10 wherein over 90% of patients were disease free at 2 years. However, the use of chemotherapy in Europe was producing surprisingly little improvement in survival over that achieved by amputation alone. Both the E.O.R.T.C. Studies and that undertaken by the Medical Research Council (M.R.C.) in the United Kingdom were disappointing, although in retrospect it is clear that the intensity of chemotherapy was inadequate [1,2]. At the same time the Mayo Clinic was reporting a survival of 50% with surgery alone and no chemotherapy, one of their explanations being that the natural history of the disease had changed and that chemotherapy was no longer necessary .
KeywordsClin Oncol Medical Research Council Cancer Study Group Study Scheme Considerable Confusion
Unable to display preview. Download preview PDF.
- 3.Edmondson JH, Green SJ, Ivins JC, et al. A controlled pilot study of high-dose methotrexate: a postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol 2:156, 1984.Google Scholar
- 4.Link MP. Adjuvant therapy in the treatment of osteosarcoma. In: Important Advances in Oncology. De Vita VT, Helson S, Rosenberg SA, Eds. Lippincott, Philadelphia, J.B. 1986, pp 193–207.Google Scholar